# OnCo record paper-keynote-811-janjigian-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-811-janjigian-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-811-janjigian-lancet-2023" ;
  schema:name "KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma"@en ;
  schema:description "Adding pembrolizumab to trastuzumab and chemotherapy improved response and progression-free survival in HER2-positive advanced gastric cancer, with the benefit concentrated in tumours that also express PD-L1."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-811-janjigian-lancet-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(23)02033-0>, <https://pubmed.ncbi.nlm.nih.gov/37871604/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)02033-0> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Janjigian YY, Kawazoe A, Bai Y, et al." ;
  onco:cancers <https://onco.cc/cancers/gastric-her2-positive/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:trials <https://onco.cc/trials/keynote-811/> ;
  onco:journals <https://onco.cc/journals/lancet/> .